Medicare AdvantageCoverageMedium impact
MA08.129b, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated medical necessity criteria and medical coding requirements for Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo®), a combination drug used in cancer treatment. This change affects billing and coverage criteria for this specific oncology medication.
Action Required
By November 17, 2025: Billing team must review updated medical necessity criteria for Phesgo® (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) for Medicare Advantage plans. Access the full policy at the provided URL to understand new coding requirements and ensure proper documentation of medical necessity before billing. Update billing protocols to comply with new criteria to avoid claim denials.